Clinical trials: Dementia, Lewy Body
Dementia With Lewy Bodies
Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
Multi-center, randomized, double-blind, placebo-controlled, 6- month study in subjects with mild to moderate Dementia with Lewy Bodies.
- Trial name
- COG1201 (NCT05225415)
- Testing
- CT1812
- Where
- 34 sites in United States
- Volunteers
- 130 people
- Sponsor
- Cognition Therapeutics
Lewy Body Dementia, Dementia With Lewy Bodies
Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder
This study seeks to evaluate the long-term safety and effectiveness of nelotanserin for the treatment of visual hallucinations (VHs) and Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with Lewy body dementia…
- Conditions
- Lewy Body Dementia, Dementia With Lewy Bodies, Parkinson's Disease Dementia, Visual Hallucinations
- Trial name
- NCT02871427
- Testing
- Nelotanserin
- Where
- 19 sites in United States
- Volunteers
- 80 people
- Sponsor
- Axovant Sciences Ltd.
Alzheimer's Disease, Dementia
Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia
The objective of the study is to define the performance of blood-based signatures for Alzheimer's Disease (AD) in different patients populations including AD, non-AD dementia, and non-demented controls.
- Trial name
- NCT00880347
- Testing
- Blood sampling
- Where
- 21 sites in France
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Exonhit
Healthy Volunteers
A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)
The purpose of this healthy volunteers drug-drug interaction study is to assess the CYP1A2 and CYP3A4 perpetrator interaction potential and CYP1A2 victim potential of TEV-56286 (anle138b).
- Trial name
- NCT05532358
- Testing
- anle138b (TEV-56286), Fluvoxamine 100 mg QD for 5 days
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Lewy Body Disease
Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies
TRIAL SUMMARY: This is an open-label, 24-week, investigator initiated study to evaluate the safety and efficacy of galantamine (16 8 to 24 mg/day; flexible dosing) in the treatment of Dementia with Lewy bodies.
- Trial name
- NCT00230997
- Testing
- Galantamine
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Neurological Research Center
Alzheimer Disease, Mild Cognitive Impairment
Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders
The primary objective of the study is to evaluate the feasibility of eliciting continuous narrative speech in different neurodegenerative and psychiatric indications, using remote, self-administered speech tasks, as measured by…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia With Lewy Bodies, Dementia, Vascular
- Trial name
- RHAPSODY (NCT04939818)
- Where
- 2 sites in United Kingdom
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Cognitive Dysfunction, Lewy Body Disease
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily…
- Conditions
- Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
- Trial name
- NCT07589595
- Testing
- Donanemab
- Where
- 72 sites in United States, Japan and 2 more
- Volunteers
- 350 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease (AD), Frontotemporal Lobar Degeneration
ADDIA Proof-of-Performance Clinical Study
The objective of the ADDIA clinical Proof-of-Performance study is to validate the performance of ADDIA' blood biomarkers for diagnosis of Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease (AD), Frontotemporal Lobar Degeneration, Dementia with Lewy Bodies (DLB), Parkinson Disease Dementia (PDD)
- Trial name
- ADDIA (NCT03030586)
- Testing
- volumetric MRI
- Where
- 13 sites in Belgium, France and 3 more
- Volunteers
- 821 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer's Disease, Dementia With Lewy Bodies
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
This study seeks to evaluate the effect of intepirdine (RVT-101) on gait and balance in patients with Alzheimer's Disease, Dementia with Lewy Bodies or Parkinson's Disease Dementia.
- Conditions
- Alzheimer's Disease, Dementia With Lewy Bodies, Parkinson's Disease Dementia
- Trial name
- NCT02910102
- Testing
- RVT-101 35 mg
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- Axovant Sciences Ltd.
Dementia With Lewy Bodies (DLB)
Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies
This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled, proof-of-principle study of neflamapimod versus matching placebo (randomized 1:1) administered with food for 16 weeks in subjects with DLB.
- Trial name
- AscenD-LB (NCT04001517)
- Testing
- Neflamapimod
- Where
- 24 sites in United States, Netherlands
- Volunteers
- 91 people
- Sponsor
- EIP Pharma Inc
Dementia With Lewy Bodies
Expanded Access Program for CT1812 (Zervimesine)
This is a multi-center, open label, expanded access program (EAP) that will provide 100 mg CT1812 for up to one year to participants with mild-to-moderate DLB.
- Trial name
- NCT06961760
- Testing
- zervimesine
- Where
- 8 sites in United States
- Sponsor
- Cognition Therapeutics
Dementia With Lewy Bodies
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
The purpose of this study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB.
- Trial name
- NCT05869669
- Testing
- Neflamapimod
- Where
- 40 sites in United States, Netherlands and 1 more
- Volunteers
- 159 people
- Sponsor
- EIP Pharma Inc
Alzheimer's Disease, Lewy Body Dementia
Pulsed Electromagnetic Field Treatment With Dementia Patients
An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices.
- Conditions
- Alzheimer's Disease, Lewy Body Dementia, Vascular Dementia
- Trial name
- NCT06862557
- Testing
- ECHS AD Device
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Herrick Medical LLC
Dementia, Lewy Body, Lewy Body Disease
A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)
The purpose of this study is to confirm the efficacy of Aricept in patients with dementia with Lewy bodies (DLB).
- Trial name
- NCT02345213
- Testing
- E2020
- Where
- Japan
- Volunteers
- 160 people
- Sponsor
- Eisai Co., Ltd.
Alzheimer Disease, Alzheimer Dementia
Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study
The purpose of the study is to evaluate the use of autologous Bone Marrow Derived Stem Cells (BMSC) as a means to improve cognitive impairment as occurs in Alzheimer's Disease and other dementias and to improve behavior and…
- Conditions
- Alzheimer Disease, Alzheimer Dementia, Vascular Dementia, Lewy Body Disease
- Trial name
- ACIST (NCT03724136)
- Testing
- Intravenous Bone Marrow Stem Cell (BMSC) Fraction, Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction, Near Infrared Light
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 100 people
- Sponsor
- MD Stem Cells
Mild Cognitive Impairment, Dementia
COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE
This retrospective study is a more extensive, confirmatory analysis of the cognitive and functional outcomes initially seen in 2 groups of MCI/dementia patients in Springfield, MA and compares specialized dementia care and a…
- Conditions
- Mild Cognitive Impairment, Dementia, Hypoxia, Hyperhomocysteinemia
- Trial name
- NCT02860338
- Volunteers
- 900 people
- Sponsor
- Clionsky Neuro Systems Inc.
Lewy Body Dementia Psychosis
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
- Trial name
- NCT07095465
- Testing
- ACP-204
- Where
- 36 sites in United States, Bulgaria and 4 more
- Volunteers
- 126 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Dementia With Lewy Bodies
A Study to Assess Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies
To establish the safety and efficacy of HTL0018318 compared with placebo when administered once daily for 12 weeks to patients with dementia with Lewy bodies.
- Trial name
- DLB (NCT03592862)
- Testing
- HTL0018318
- Where
- 3 sites in Japan
- Sponsor
- Nxera Pharma UK Limited
Dementias With Lewy Bodies
A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants
The primary objective of the study is to achieve mass balance recovery of [14C]-radiolabel in urine and feces and to identify and quantify the main elimination pathways of E2027.
- Trial name
- NCT04023877
- Testing
- E2027
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Lewy Body Disease
A Phase I Study of GT300 in Healthy Subjects
Descriptive safety and pharmacokinetics of GT300, exploratory biomarker effects for the evaluation of the effect of GT300 on the autophagy-lysosomal pathway (ALP), food effect on PK and fasting effect on biomarkers.
- Trial name
- NCT04963855
- Testing
- GT300, Microcrystalline cellulose
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Generian Pharmaceuticals, Inc.